2012

Mechanisms of remodeling in asthmatic airways

Adrian Shifren  
*Washington University School of Medicine in St. Louis*

Chad Witt  
*Washington University School of Medicine in St. Louis*

Chandrika Christie  
*Washington University School of Medicine in St. Louis*

Mario Castro  
*Washington University School of Medicine in St. Louis*

Follow this and additional works at: [https://digitalcommons.wustl.edu/open_access_pubs](https://digitalcommons.wustl.edu/open_access_pubs)

Part of the Medicine and Health Sciences Commons

**Recommended Citation**

Shifren, Adrian; Witt, Chad; Christie, Chandrika; and Castro, Mario, "Mechanisms of remodeling in asthmatic airways." *Journal of Allergy*. 2012,. Article ID 316049. (2012).  
[https://digitalcommons.wustl.edu/open_access_pubs/970](https://digitalcommons.wustl.edu/open_access_pubs/970)

This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker. For more information, please contact vanam@wustl.edu.
Mechanisms of Remodeling in Asthmatic Airways

Adrian Shifren, Chad Witt, Chandrika Christie, and Mario Castro

Division of Pulmonary and Critical Care Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA

Correspondence should be addressed to Mario Castro, castrom@dom.wustl.edu

Received 9 June 2011; Revised 7 September 2011; Accepted 10 October 2011

Asthma is a chronic inflammatory airway disorder characterized by airway hyperresponsiveness and reversible airflow obstruction. Subgroups of asthma patients develop airflow obstruction that is irreversible or only partially reversible and experience an accelerated rate of lung function decline. The structural changes in the airways of these patients are referred to as airway remodeling. All elements of the airway wall are involved, and remodeled airway wall thickness is substantially increased compared to normal control airways. Airway remodeling is thought to contribute to the subphenotypes of irreversible airflow obstruction and airway hyperresponsiveness, and it has been associated with increased disease severity. Reversal of remodeling is therefore of paramount therapeutic importance, and mechanisms responsible for airway remodeling are feasible therapeutic targets for asthma treatment. This paper will focus on our current understanding of the mechanisms of airway remodeling in asthma and potential targets for future intervention.

1. Introduction

Asthma is a chronic inflammatory disorder of the airways characterized by airway hyperresponsiveness (AHR) and reversible airflow obstruction that fluctuates over time. Asthma used to be considered a single disease entity, but is increasingly recognized as a disease with multiple subphenotypes that differ in clinical severity, pathological findings, response to therapy, and long-term outcome [1]. A subgroup of this heterogeneous group of asthma patients manifests airflow obstruction that is either irreversible or only partially reversible. Furthermore, some of these patients experience an accelerated rate of decline in respiratory function compared to healthy controls [2, 3]. In children with asthma defined by wheezing diagnosed at age 7 and followed for 21 years, lung function was essentially normal in patients who ceased wheezing but was increasingly abnormal in those patients who continued to wheeze frequently throughout life [4].

Airway inflammation, tissue injury, and subsequent abnormal repair lead to structural changes in the airway walls of asthmatic subjects collectively referred to as airway remodeling. Airway remodeling is strongly suspected to result in the physiologic subphenotypes of irreversible or partially reversible airflow obstruction and accelerated lung function decline [5]. Almost all elements of the airway wall have been shown to be altered in fatal asthma [6, 7]. The changes occur throughout the bronchial tree [8], but are most marked in large membranous and small cartilaginous airways [9]. Similar findings occur in nonfatal asthma, although they are less profound and localized predominantly to midsized and small membranous airways less than 3 mm in diameter [6, 10]. This review will focus on our current understanding of the pathology, pathogenesis, and physiologic consequences of airway remodeling in asthma, and discuss potential targets for therapeutic intervention.

2. Pathology and Pathogenesis of Airway Remodeling

2.1. Airway Wall Thickening. In fatal asthma, airway wall thickness is increased by between 50 and 230% compared to normal controls, while in nonfatal asthma, the increase ranges from 25–150% [11]. Increased wall thickening has repeatedly been associated with increased disease severity, including near fatal asthma [12–14]. These changes are the result of epithelial cell alterations, subepithelial fibrosis, submucosal gland hyperplasia, increased airway smooth muscle mass, and increased airway vascularization [10, 15–17].
2.2. Allergic Airway Inflammation. Chronic inflammation that results in tissue injury with subsequent structural change during tissue repair is a well-documented biological phenomenon, for example, cirrhosis. Since chronic airway inflammation is a striking feature of asthma, asthmatic airway inflammation is often assumed to be the initiating event for airway remodeling [21]. Most, but not all, asthma is associated with atopy, and as such, asthma has largely been regarded as an allergic disease [22]. In keeping with this premise, a cellular infiltrate rich in lymphocytes, eosinophils, mast cells, neutrophils, and macrophages [5] characterizes asthmatic airway inflammation. Lymphocytic inflammation is dominated by Th2-cells producing interleukin (IL)-4, IL-5, and IL-13 (Figure 1) [23]. Overexpression of Th2 interleukins in mouse models has demonstrated changes pathognomonic of asthmatic airway remodeling. Overexpression of IL-13 resulted in subepithelial fibrosis, mucus metaplasia, and an inflammatory infiltrate rich in eosinophils and macrophages [24]. IL-5 overexpression induced striking airway eosinophilia, along with mucus metaplasia and
subepithelial fibrosis [25]. While IL-4 overexpression led to eosinophilia and mucus metaplasia, subepithelial fibrosis in IL-4 overexpressing models has been unimpressive or absent depending on the study [26, 27]. In addition, mice overexpressing all three of these Th2 interleukin molecules demonstrated AHR. Eosinophils and mast cells likely impact the epithelial remodeling based on effects on barrier function, epithelial proliferation and desquamation, and goblet cell formation [28]. These data indicate that airway remodeling is quite likely driven in part by the Th2 inflammation characteristic of the asthmatic airway.

Several lines of evidence in animal models and humans suggest that the Th2 hypothesis is an incomplete explanation for asthma pathogenesis. First, many patients with asthma do not have an identifiable allergic trigger for their disease. Conversely, a significant number of patients with atopy do not develop asthma [29]. Taken together, it is reasonable to deduce that other triggers exist for generating asthma. Second, the allergic and nonallergic forms of asthma are pathologically indistinguishable from each other [30], implying that remodeling occurs independent of atopic inflammation. This suggests a remodeling pathway common to all forms of remodeled asthma. Third, current anti-inflammatory and allergen-reduction therapies (see below) do not prevent the development of asthma or effectively reverse airway remodeling once it has occurred [31]. Lastly, airway remodeling occurs simultaneously with inflammation and may indeed be necessary for the establishment of a chronic inflammatory state [32]. These observations have encouraged exploration of alternative mechanisms of airway injury as the underlying mechanism of airway remodeling.

2.3. Epithelial-Driven Models of Airway Remodeling. While it is likely that some aspects of airway remodeling are the end result of allergen exposure and subsequent chronic allergic inflammation, it is increasingly believed that predisposition to asthma lies in a structurally and functionally defective airway epithelium which links the inhaled environment to underlying airway structures. This phenomenon is best explained by the model of the epithelial mesenchymal tropic unit or EMTU proposed by Holgate [33] and reviewed in [34, 35]. In this model, both airway inflammation and remodeling are the consequence of repetitive environmental injury to a defective airway epithelium by viruses, air pollutants, or tobacco smoke (Figure 1) [22]. Injury leads to interaction between the dysfunctional epithelium and the underlying mesenchyme that results in amplification of the inflammatory and remodeling responses in the underlying layers of the airway wall with subsequently defective airway repair [35].

Support for this model is increasingly robust. Evidence, primarily from animal models, indicates that innate immune responses to respiratory virus infections, for example, contribute to the development of inflammatory airway disease characteristic of asthma [36–39]. Paramyxoviral infection of mice has been shown to produce acute bronchiolitis resulting in airway inflammation and AHR. However, infection also results in a chronic inflammatory response with airway remodeling and AHR phenotypes [40]. This chronic response is not only strikingly similar to the inflammatory response in the airways of asthmatic patients, but also persists for over a year after mice have cleared the virus from the airways. It has subsequently been shown that the chronic inflammatory state is related to the severity of infection and is produced by an innate epithelial immune response in which natural killer T cells activate macrophages to produce proinflammatory cytokines like IL-13, which contribute to chronic mucous cell metaplasia [41] and are reviewed in [42, 43]. The mouse model correlates well with clinical findings. Paramyxoviral infections are a primary cause of lower respiratory tract infection in infants and children [44], and children with severe RSV bronchiolitis are predisposed to development of a chronic wheezing illness in the absence of both atopy and viral persistence in airway tissue [45, 46].

2.4. Epithelial Cell Alterations. Epithelial cell shedding, cilium loss, and goblet cell hyperplasia have all been described in asthmatic airways [6, 15, 47]. Epithelial shedding has been noted in postmortem studies of asthmatic airways, and sputum and BAL samples from asthmatic patients contain increased amounts of epithelial cells [6, 48]. However, epithelial cell desquamation in bronchial biopsy specimens from healthy nonasthmatic subjects appears similar to that seen in biopsies from mild to severe asthmatics [49, 50] suggesting that this phenomenon is related to the sampling technique itself. Evidence of increased epithelial cell proliferation contributing to thickening of the epithelium and an increased lamina reticularis (also known as subepithelial fibrosis, see below) has been observed in patients with moderate to severe asthma (Figure 2) while being absent in patients with mild persistent asthma, chronic bronchitis, and normal controls [49]. These studies suggest that thickening of the airway seen in severe asthma may be due, in part, to airway epithelial proliferation (Figure 3), although conflicting data exist (see below).

Goblet cell hyperplasia has been consistently demonstrated in mild, moderate, and severe forms of asthma (Figure 3), although the finding is particularly apparent in severe and fatal asthma [51, 52]. Similarly, an increase in the area of airway wall occupied by submucosal mucus glands is a frequent finding in asthmatic airways, and occurs in both fatal and nonfatal forms of asthma [6]. Goblet cells produce mucin glycoproteins (MUC), 13 of which have been identified in human airways [53]. The dominant mucin in humans is MUC5AC, which is expressed in the airways of normal subjects and is upregulated in asthmatic subjects [54]. Goblet cell hyperplasia has been demonstrated following adoptive transfer of Th2 cells into ovalbumin-challenged mice [55]. This is most likely the result of Th2-driven interleukin expression (see above). IL-13, in particular, signals through the STAT-6 signaling pathway [5] and the effects of IL-13 overexpression in mice are almost completely STAT-6 dependent [56].

Other changes observed in the airway epithelium lend support to the EMTU hypothesis of asthma pathogenesis. Epithelial injury is normally followed by upregulation of proteins responsible for tissue repair. Expression of epithelial growth factor receptor (EGFR) and MUC5AC are both
markedly upregulated in the epithelium of asthmatic patients [57, 58], and have been shown to colocalize in goblet cells [59]. Immunoreactivity to EGFR and the total area of MUC5AC staining show a positive correlation in both asthmatics and control subjects. Furthermore, activation of EGFR has been shown to upregulate both mucin production and goblet cell generation in human epithelial cells in vitro [57]. Interestingly, increased airway expression levels of EGFR are not associated with markers of increased cell proliferation as would be expected in tissue undergoing active repair [60] suggesting an innate defect of the asthmatic epithelium to repair itself.

2.5. Subepithelial Fibrosis. The original report of airway remodeling described the phenomenon of basement membrane thickening [61]. Electron microscopy has subsequently shown that thickening occurs just below the true basement membrane in a zone known as the lamina reticularis [17]. The lamina reticularis (Figure 2) is a collagenous layer 4-5 μm thick in control subjects. In asthmatics, lamina reticularis thickness has been documented at between 7 and 23 μm [62]. Thickening is the result of extracellular matrix deposition, primarily collagens I, III, and V [5]. In addition, abnormalities of noncollagenous matrix, including elastin, fibronectin, tenascin, lumican, and proteoglycans, have also been described [17, 63, 64].

Subepithelial fibrosis occurs in children, and is similar in extent to that seen in adults [65] suggesting that it is an early finding of asthmatic airway remodeling. Subepithelial fibrosis has also been reported in all severities of asthma [9, 66]. However, the specificity of subepithelial fibrosis is called into question by studies that have identified severe asthmatics without subepithelial fibrosis, and nonasthmatic subjects with significant fibrosis [67–69]. Furthermore several functional measurements of asthma show variable correlations with the degree of fibrosis [66, 70–72] raising questions about its functional consequences.

Myofibroblasts are probably key effectors of subepithelial fibrosis. Myofibroblasts are specialized cells with phenotypic characteristics of both fibroblasts and myocytes [53]. They express α-smooth muscle actin, produce inflammatory mediators, and are major producers of extracellular matrix proteins necessary for tissue repair and remodeling.

Transforming growth factor- (TGF-) β mediates the effects of IL-13 overexpressing mice [73]. TGF-β is a cytokine produced by multiple lung cells including epithelial cells, macrophages, fibroblasts, lymphocytes, and eosinophils [53]. TGF-β induces fibroblasts to express α-smooth muscle actin and assume a myofibroblast phenotype [74]. As part of normal wound repair, TGF-β induces expression and secretion of multiple extracellular matrix proteins while also inhibiting their degradation. In many diseases, excessive TGF-β
results in an excess of pathologic tissue fibrosis leading to compromised organ function [75]. Compared to controls, TGF-β expression is increased in asthmatic airways and BAL fluid. In addition, TGF-β levels correlate with the extent of subepithelial fibrosis, airway fibroblast numbers, and disease severity [76–78]. Thus, excess TGF-β production may be pivotal for the development of subepithelial fibrosis.

Matrix metalloproteinases are zinc-dependent endopeptidases capable of degrading extracellular matrix molecules. The dynamic equilibrium between matrix metalloproteinases and their inhibitors is a critical determinant of matrix remodeling [79]. The existence of increased subepithelial fibrosis in asthmatic airways strongly suggests that a profibrotic balance exists between the two. In asthma, the most important metalloproteinase molecules are MMP-9 and its inhibitor, tissue inhibitor of metalloproteinase-1 (TIMP-1) [5]. Both MMP-9 and TIMP-1 levels are elevated in airway biopsies and BAL fluid of asthmatic patients [80–82]. However, compared to control subjects, asthmatics have a significantly lower MMP-9 to TIMP-1 ratio supporting a profibrotic balance (inhibition over degradation). In addition, the lower MMP-9 to TIMP-1 ratios correlate with the degree of airway obstruction [83].

TGF-β is secreted from cells as a latent complex and is targeted to the extracellular matrix by latent TGF-β binding proteins for subsequent activation [84]. MMPs regulate matrix-bound cytokine release [83], and activation of TGF-β is MMP-9 dependent [73]. Therefore, the role of elevated levels of MMP-9 in asthma may be related to TGF-β activation and its downstream fibrotic sequelae [5].

Thickening of the lamina reticularis provides further evidence for the idea of a dynamically interactive EMTU. Epithelial disturbances have been shown to result in increased levels of fibrogenic growth factors including both the latent and active forms of TGF-β [33, 85]. This response is enhanced in asthmatic epithelium compared to normal controls, and the fibrogenic factors have been shown to localize in mesenchymal elements underlying the injured epithelium [86, 87] including the lamina reticularis. Thus, the lamina reticularis may act as a conduit for transmission of signals from an innately defective epithelium to deeper tissues of the airway wall.

2.6. Increased Airway Smooth Muscle Mass. Increased airway smooth muscle (ASM) mass is the most prominent feature of airway remodeling [6], with ASM mass increasing disproportionately compared to the increase in total wall thickness [53]. It has been documented in both fatal and nonfatal asthma [11], and correlates with both disease severity and duration, being greater in fatal than nonfatal cases of asthma [6, 7, 10] and greater in older patients with fatal asthma than younger patients with fatal disease.

The increase in ASM mass may be the coordinated result of increased myocyte size (hypertrophy), increased myocyte number (hyperplasia), and potentially differentiation and migration of mesenchymal cells to ASM bundles [88–91]. Controversy exists regarding the relative contributions of hypertrophy and hyperplasia to ASM mass increases. The evidence for hyperplasia is relatively convincing [90, 92]. However, support for hypertrophy is conflicting, in part because documentation of increased cell size (width) may be subject to artifact resulting from cell shortening [32]. While studies have documented hypertrophy of ASM in severe asthma, particularly in smaller airways, other studies found no evidence for ASM hypertrophy in mild-moderate asthma [32].

Mitogens are chemical compounds that stimulate cell division and trigger mitosis. Mitogens play an integral role in the development of increased ASM mass typical of asthmatic airways. Mitogens bind receptor tyrosine kinases (RTK), G protein-coupled receptors (GPCR), and cytokine receptors. These receptor systems are all capable of producing increases in ASM mass in cell culture models [53]. The list of mitogens is extensive, and includes TGF-β, IL-1β, IL-6, thromboxanes, leukotrienes, histamine, tryptase, serotonin, vascular endothelial growth factor (VEGF), and numerous others [89, 93, 94]. The receptor systems regulate mitogenesis primarily through the phosphoinositide 3'-kinase (PI3K) and extracellular signal-regulated kinase (ERK) signaling pathways [95, 96]. The PI3K and ERK pathways activate transcription factors which phosphorylate D-type cyclins facilitating cell cycle progression [53]. Almost all of these mitogens have been identified in airway biopsies and BAL fluid from asthmatic patients or are detected in asthmatic airway cell cultures [21]. They may therefore represent targets for modulation of airway smooth muscle in asthmatic disease.

ASM cells are often noted in close proximity to the airway epithelium. This epithelial-muscle distance was measured at 67 μm in asthmatics compared to 135 μm in controls [70]. It has been postulated that mesenchymal airway cells differentiate into ASM with subsequent migration of the new ASM cells into muscle bundles [97]. Whether these phenomena occur in vivo is unknown, but reports indicate that cultured human ASM cells migrate in response to mitogenic stimuli [98]. Many of the mitogens involved in cell proliferation also induce ASM cell migration including TGF-β, IL-1β, and VEGF [21, 53].

2.7. Bronchial Neovascularization. Increased vascularity is frequently associated with chronic inflammation, and increased airway vascularity is well documented in asthma [16, 99]. Compared to controls, bronchial biopsies from asthmatic patients demonstrate an increase in the number and cross-sectional area of blood vessels, predominantly capillaries and venules, especially in the lamina propria [98, 100, 101]. It has been suggested that neovascularization worsens disease through increased vascular congestion, airway edema and inflammation, and global wall thickening [5]. In support of this idea, increases in airway vessel number have been shown to correlate with both disease severity and AHR [100, 102, 103].

VEGF is an angiogenic growth factor. It is a mitogen for vascular endothelial cells inducing endothelial cell proliferation and migration while inhibiting apoptosis. VEGF is an important factor in diseases associated with abnormal angiogenesis and wound repair [104]. Overexpression of VEGF in mice induces marked airway angiogenesis along with significant airway edema [105]. Interestingly, VEGF overexpressing
mice also demonstrate increased Th2 cytokine expression, including IL-13 and TGF-β, and have evidence of subepithelial fibrosis and increased ASM mass. Furthermore, IL-13 overexpression is associated with increased levels of VEGF suggesting that a positive feedback loop promoting Th2 polarization may exist in asthmatic airways [106]. VEGF levels in sputum and BAL fluid from asthmatics are significantly increased and appear to correlate with disease activity [98, 107, 108].

3. Physiologic Consequences of Airway Remodeling

Functional data increasingly support the idea that remodeling-induced structural changes contribute to the subphenotypes of AHR and irreversible or partially reversible airflow obstruction [109, 110]. There are many potential etiologic mechanisms that link altered airway anatomy and asthmatic pathophysiology, but most are beyond the scope of this review.

The role of small airways in producing airflow obstruction and AHR seems to be greater than that of larger airways [111, 112]. Peripheral lung resistance is increased in all severities of asthma, even mild cases [113, 114]. Heterogeneity of peripheral bronchoconstriction is a major determinant of airflow obstruction, creating large increases in the load against which patients must breath [115, 116]. Although heterogeneous bronchoconstriction is well documented in wild-type animals and nonasthmatic human subjects [117–119], mathematical models indicate that heterogeneity of peripheral bronchoconstriction is significantly increased in asthmatic patients when compared to normal controls [120, 121].

Increased ASM mass is thought to be the most likely cause of AHR [122]. Asthmatic ASM exhibits increased contractility [123, 124], a finding initially ascribed to increased total ASM mass [7, 8, 10]. However, results from studies comparing ASM force generation in asthmatic ASM and normal controls are contradictory [125–127], in large part because of the difficulty in normalizing measured force to ASM mass [128]. A more likely explanation of AHR in asthmatic patients is an increase in the maximal velocity of shortening (Vmax) of ASM cells [128, 129]. Experimental evidence supporting an increase in Vmax includes data from human [124, 130] and animal models [131].

Noncontractile elements of airway remodeling also contribute to AHR [109]. Increased airway extracellular matrix is one noncontractile element that may contribute to AHR. Decreased airway compliance is well documented in asthmatic patients [132, 133] and has been found to correlate inversely, although weakly, with increases in subepithelial fibrosis [134]. Therefore, increased extracellular matrix content may contribute to nonreversible airflow obstruction by reducing airway distensibility. It has also been postulated that increases in extracellular matrix lead to an excess of matrix-bound cytokines and retention of soluble inflammatory mediators [135]. This results in worsening airway inflammation with subsequent chronic persistence of established AHR.

Finally, contractile and noncontractile elements of the remodeled airway wall may interact to increase airflow obstruction and AHR. Application of cyclic stresses to airway segments reduces ASM contractility [136, 137]. Decreased airway distensibility may reduce the cyclic stresses transmitted to ASM during breathing, reducing the cyclical stretching of ASM [138, 139]. ASM adapts to this attenuated stimulus by assuming a shorter resting length while retaining its ability to generate force. This mechanical plasticity, as the phenomenon is known, is an important feature of ASM biology affecting its contractile function [140]. The shortened muscle fibers enhance the airways predisposition to undergo excessive constriction during stimulation [110].

4. Therapeutic Targets for Airway Remodeling

The natural history of airway remodeling is poorly understood [9]. While the physiologic subphenotypes are more obvious in older patients with more severe disease of longer duration [141], airway remodeling is known to occur early on in the disease course [32]. Clinical trials of therapeutic intervention to prevent airway remodeling are currently lacking. Reversal of existing remodeling is therefore an important therapeutic objective since remodeling may often be present even at the time of asthma diagnosis.

4.1. “Anti-Inflammatory” Therapy. Animal studies of allergen-challenged models suggest that airway remodeling can be prevented, but also suggest that it cannot be fully reversed once initiated [142]. In general, therapies aimed at immunomodulation have proved disappointing. These include therapies directed against T cells (azathioprine, cyclosporine, and methotrexate) and Th-2 cytokine blockade (IL-4, IL-5 (see below) and IL-13) [143]. Some positive clinical data has been obtained, specifically with the use of corticosteroids, but in general, the data are mixed. In one study, treatment of asthmatic patients with inhaled corticosteroids (ICS) for 1 year demonstrated reductions in both subepithelial fibrosis and AHR [144]. The authors attributed the decrease in AHR to both reduced airway remodeling and decreased airway inflammation. However, other studies have shown mixed results. While they have demonstrated significant reductions in AHR, these same studies demonstrated either lack of airway remodeling after 8 weeks of ICS therapy [145], or no change in lung function (specifically postbronchodilator FEV1% predicted) when compared to placebo, despite treatment with ICS for 4 to 6 years [146].

4.2. Targeted Immunotherapy. Airway eosinophils are a key component of Th2 inflammation and are thought to be key effectors of both chronic inflammation and airway remodeling in asthma [21]. IL-5 is a key mediator of eosinophil activation and results in increase in the number of circulating, airway, and sputum eosinophils in mice [147]. Initial trials with mepolizumab, an anti-IL-5 monoclonal antibody, were disappointing. Although circulating eosinophils were dramatically reduced, airway eosinophils were only depleted.
by approximately 55% and there was no observable effect on circulating T cells [148, 149]. In addition, no significant effect on asthma outcomes or AHR were noted [149–151]. Subsequent trials of mepolizumab in severe asthma patients with persistent sputum eosinophilia have demonstrated a significant reduction in airway wall thickness measured by quantitative CT scanning (RB1 W A%/body surface area). In addition, significant reductions in the levels of circulating and sputum eosinophils were also noted when compared to placebo [152, 153]. However, no effects on AHR were identified.

Treatment with omalizumab, an anti-human IgE monoclonal antibody, has well-documented efficacy in improving asthma outcomes in a subgroup of patients with moderate to severe persistent asthma [154–159]. Patients in this subgroup demonstrate a confirmed atopic component and remain uncontrolled despite high-dose inhaled corticosteroids and at least one additional controller therapy [160]. Omalizumab inhibits the binding of IgE to the high-affinity IgE receptor (FceRI). It does so by binding to an epitope on the IgE molecule to which the FceRI would bind [161]. Omalizumab resulted in significant reductions in sputum eosinophil counts and an 80% reduction in the number of airway tissue eosinophils. Even more striking was an almost complete reduction in airway cells staining positive for FceRI (including basophils and mast cells) and a significant decrease in the number of airway T and B cells [162].

The therapeutic utility of anti-IgE therapy stands in stark juxtaposition to that of anti-IL-5 therapy. The differences suggest that either the (relatively) small reduction in airway eosinophilia mediated by IL-5 blockade is insufficient to produce a therapeutic effect, or that the effects of anti-IgE therapy result from attenuation of multiple effector cells in the asthmatic inflammatory cascade and not solely a reduction in tissue eosinophils [35].

### 4.3. Bronchial Thermoplasty

Bronchial thermoplasty (BT) delivers thermal energy to the airway wall in a controlled manner to reduce excessive ASM [163]. The procedure has been well studied in severe persistent asthma that is not well controlled with inhaled corticosteroids and long-acting beta-agonists [164, 165]. Long-term followup of BT study patients supports the efficacy and safety of BT out to 5 years [166]. Lung function (FEV1 and FVC) remained stable over five years of followup. However, while studies have established small but significant improvements in PC20 doubling in patients undergoing BT when compared to controls for periods of up to 3 years after the procedure [166], there has in general been a lack of evidence demonstrating reduction in AHR. In the largest trial of bronchial thermoplasty to date [164], a subset of participants (100 treated with thermoplasty, 50 received sham bronchoscopy) underwent CT scans before and one year after treatment. Qualitative analysis of these images demonstrated no evidence of airway or parenchymal injury related to bronchial thermoplasty and an increase in bronchial wall thickening in those receiving sham bronchoscopy [167]. Therefore, thermoplasty may represent a mechanism by which smooth muscle can be abrogated resulting in the prevention of progressive remodeling in severe asthma.

### 5. Conclusions

There is now a substantial body of evidence documenting typical structural changes in the airways and lung parenchyma of asthmatic patients. These changes most likely contribute to the AHR and irreversible or partially reversible airflow obstruction seen in subgroups of asthmatic patients, especially those with more severe disease. The mechanisms responsible for these changes present viable therapeutic targets for the prevention and treatment of airway remodeling in asthma.

### References

[1] G. P. Anderson, “Endotyping asthma: new insights into key pathogenic mechanisms in a complex, heterogeneous disease,” The Lancet, vol. 372, no. 9643, pp. 1107–1119, 2008.

[2] M. H. Grol, J. Gerritsen, J. M. Vonk et al., “Risk factors for growth and decline of lung function in asthmatic individuals up to age 42 years: a 30-year follow-up study,” American Journal of Respiratory and Critical Care Medicine, vol. 160, no. 6, pp. 1830–1837, 1999.

[3] P. Lange, J. Parner, J. Vestbo, P. Schnohr, and G. Jensen, “A 15-year follow-up study of ventilatory function in adults with asthma,” New England Journal of Medicine, vol. 339, no. 17, pp. 1194–200, 1998.

[4] W. J. W. Kelly, I. Hudson, J. Raven, P. D. Phelan, M. C. F. Pain, and A. Olinsky, “Childhood asthma and adult lung function,” American Review of Respiratory Disease, vol. 138, no. 1, pp. 26–30, 1988.

[5] R. J. Homer and J. A. Elias, “Airway remodeling in asthma: therapeutic implications of mechanisms,” Physiology, vol. 20, no. 1, pp. 28–35, 2005.

[6] N. Carroll, J. Elliot, A. Morton, and A. James, “The structure of large and small airways in nonfatal and fatal asthma,” American Review of Respiratory Disease, vol. 147, no. 2, pp. 405–410, 1993.

[7] A. L. James, P. D. Pare, and J. C. Hogg, “The mechanics of airway narrowing in asthma,” American Review of Respiratory Disease, vol. 139, no. 1, pp. 242–246, 1989.

[8] M. Saetta, A. Di Stefano, C. Rosina, G. Thiene, and L. M. Fabbri, “Quantitative structural analysis of peripheral airways and arteries in sudden fatal asthma,” American Review of Respiratory Disease, vol. 143, no. 1, pp. 138–143, 1991.

[9] J. A. Elias, Z. Zhu, G. Chupp, and R. J. Homer, “Airway remodeling in asthma,” Journal of Clinical Investigation, vol. 104, no. 8, pp. 1001–1005, 1999.

[10] K. Kuwano, C. H. Bosken, P. D. Pare, T. R. Bai, B. R. Wiggs, and J. C. Hogg, “Small airways dimensions in asthma and in chronic obstructive pulmonary disease,” American Review of Respiratory Disease, vol. 148, no. 5, pp. 1220–1225, 1993.

[11] A. J. James, “Relationship between airway wall thickness and airway hyperresponsiveness,” in Airway Wall Remodeling in Asthma, A. G. Stewart, Ed., pp. 1–27, CRC Press, Boca Raton, Fla, USA, 1997.

[12] N. Awadh, N. L. Müller, C. S. Park, R. T. Abboud, and J. M. Fitzgerald, “Airway wall thickness in patients with near fatal asthma and control groups: assessment with high resolution
computed tomographic scanning,” *Thorax*, vol. 53, no. 4, pp. 248–253, 1998.

[13] S. A. Little, M. W. Sproule, M. D. Cowan et al., “High resolution computed tomographic assessment of airway wall thickness in chronic asthma: reproducibility and relationship with lung function and severity,” *Thorax*, vol. 57, no. 3, pp. 247–253, 2002.

[14] A. Niimi, H. Matsumoto, R. Amitani et al., “Airway wall thickness in asthma assessed by computed tomography: relation to clinical indices,” *American Journal of Respiratory and Critical Care Medicine*, vol. 162, no. 4, pp. 1518–1523, 2000.

[15] T. Aikawa, S. Shimura, H. Sasaki, M. Ebina, and T. Takishima, “Marked goblet cell hyperplasia with mucus accumulation in the airways of patients who died of severe acute asthma attack,” *Chest*, vol. 101, no. 4, pp. 916–921, 1992.

[16] X. Li and J. W. Wilson, “Increased vascularity of the bronchiolar mucosa in mild asthma,” *American Journal of Respiratory and Critical Care Medicine*, vol. 156, no. 1, pp. 229–233, 1997.

[17] W. R. Roche, J. H. Williams, R. Beasley, and S. T. Holgate, “Subepithelial fibrosis in the bronchi of asthmatics,” *Lancet*, vol. 1, no. 8637, pp. 520–524, 1989.

[18] M. Castro, S. B. Fain, E. A. Hoffman, D. S. Gierada, S. C. Erzurum, and S. Wenzel, “Lung imaging in asthmatic patients: the picture is clearer,” *Journal of Allergy and Clinical Immunology*, vol. 128, no. 3, pp. 467–478, 2011.

[19] K. Kasahara, K. Shiba, T. Ozawa, K. Okuda, and M. Adachi, “Correlation between the bronchial subepithelial layer and whole airway wall thickness in patients with asthma,” *Thorax*, vol. 57, no. 3, pp. 242–246, 2002.

[20] R. S. Aysola, E. A. Hoffman, D. Gierada et al., “Airway remodeling measured by multidetector CT is increased in severe asthma and correlates with pathology,” *Chest*, vol. 134, no. 6, pp. 1183–1191, 2008.

[21] R. M. Pascual and S. P. Peters, “Airway remodeling contributes to the progressive loss of lung function in asthma: an overview,” *Journal of Allergy and Clinical Immunology*, vol. 116, no. 3, pp. 477–486, 2005.

[22] S. T. Holgate, H. S. Arshad, G. C. Roberts, P. H. Howarth, P. Thurner, and D. E. Davies, “A new look at the pathogenesis of asthma,” *Clinical Science*, vol. 118, no. 7, pp. 439–450, 2010.

[23] L. Cohn, J. A. Elias, and G. L. Chupp, “Asthma: mechanisms of disease persistence and progression,” *Annual Review of Immunology*, vol. 22, pp. 789–815, 2004.

[24] Z. Zhu, R. J. Homer, Z. Wang et al., “Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production,” *Journal of Clinical Investigation*, vol. 103, no. 6, pp. 779–788, 1999.

[25] J. J. Lee, M. P. McGarry, S. C. Farmer et al., “Interleukin-5 expression in the lung epithelium of transgenic mice leads to pulmonary changes pathognomonic of asthma,” *Journal of Experimental Medicine*, vol. 185, no. 12, pp. 2143–2156, 1997.

[26] S. Jain-Vora, S. E. Wert, U. A. Temann, J. A. Rankin, and J. A. Whitsett, “Interleukin-4 alters epithelial cell differentiation and surfactant homeostasis in the postnatal mouse lung,” *American Journal of Respiratory Cell and Molecular Biology*, vol. 17, no. 5, pp. 541–551, 1997.

[27] J. A. Rankin, D. E. Picarella, G. P. Geba et al., “Phenotypic and physiologic characterization of transgenic mice expressing interleukin 4 in the lung: lymphocytic and eosinophilic inflammation without airway hyperreactivity,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 93, no. 15, pp. 7821–7825, 1996.

[28] S. Balzar, M. L. Fajt, S. A. A. Comhair et al., “Mast cell phenotype, location, and activation in severe asthma: data from the severe asthma research program,” *American Journal of Respiratory and Critical Care Medicine*, vol. 183, no. 3, pp. 299–309, 2011.

[29] N. Pearce, J. Pekkanen, and R. Beasley, “How much asthma is really attributable to atopy?” *Thorax*, vol. 54, no. 3, pp. 268–272, 1999.

[30] G. Turato, A. Barbato, S. Baraldo et al., “Nonatopic children with multitrigger wheezing have airway pathology comparable to atopic asthma,” *American Journal of Respiratory and Critical Care Medicine*, vol. 178, no. 5, pp. 476–482, 2008.

[31] The Lancet, “Asthma: still more questions than answers,” *The Lancet*, vol. 372, no. 9643, p. 1009, 2008.

[32] Y. Sumi and Q. Hamid, “Airway remodeling in asthma,” *Allergy International*, vol. 56, no. 4, pp. 341–348, 2007.

[33] S. T. Holgate, D. E. Davies, P. M. Lackie, S. J. Wilson, S. M. Puddicombe, and J. L. Jordan, “Epithelial-mesenchymal interactions in the pathogenesis of asthma,” *Journal of Allergy and Clinical Immunology*, vol. 105, no. 2, pp. 193–204, 2000.

[34] S. T. Holgate, “Epithelium dysfunction in asthma,” *Journal of Allergy and Clinical Immunology*, vol. 120, no. 6, pp. 1233–1244, 2007.

[35] S. T. Holgate, J. Holloway, S. Wilson, F. Bucchieri, S. Puddicombe, and D. E. Davies, “Epithelial-mesenchymal communication in the pathogenesis of chronic asthma,” *Proceedings of the American Thoracic Society*, vol. 1, no. 2, pp. 93–98, 2004.

[36] A. C. Patel, J. D. Morton, E. Y. Kim et al., “Genetic segregation of airway disease traits despite redundancy of calcium-activated chloride channel family members,” *Physiological Genomics*, vol. 25, no. 3, pp. 502–513, 2006.

[37] J. W. Tyner, E. Y. Kim, K. Ide et al., “Blocking airway mucous cell metaplasia by inhibiting EGFRII antiapoptosis and IL-13 transdifferentiation signals,” *Journal of Clinical Investigation*, vol. 116, no. 2, pp. 309–321, 2006.

[38] M. H. Grayson, D. Cheung, S. J. Ehlenbach, R. T. Kitchens et al., “Induction of high-affinity IgE receptor on lung dendritic cells during viral infection leads to mucous cell metaplasia,” *Journal of Experimental Medicine*, vol. 204, no. 11, pp. 2759–2769, 2007.

[39] D. S. Cheung, S. J. Ehlenbach, R. T. Kitchens et al., “Cutting edge: CD49d+ neutrophils induce FcεRI expression on lung dendritic cells in a mouse model of postviral asthma,” *Journal of Immunology*, vol. 185, no. 9, pp. 4983–4987, 2010.

[40] M. J. Walter, J. D. Morton, N. Kajiwara, E. Agapov, and M. J. Holtzman, “Viral induction of a chronic asthma phenotype and genetic segregation from the acute response,” *Journal of Clinical Investigation*, vol. 110, no. 2, pp. 165–175, 2002.

[41] E. Y. Kim, J. T. Battaile, A. C. Patel et al., “Persistent activation of an innate immune response translates respiratory viral infection into chronic lung disease,” *Nature Medicine*, vol. 14, no. 6, pp. 633–640, 2008.

[42] L. A. Benoit and M. J. Holtzman, “New immune pathways from chronic post-viral lung disease,” *Annals of the New York Academy of Sciences*, vol. 1183, pp. 195–210, 2010.

[43] M. J. Holtzman, D. A. Patel, Y. Zhang, and A. C. Patel, “Host epithelial-viral interactions as cause and cure for asthma,” *Current Opinion in Immunology*, vol. 23, no. 4, pp. 487–494, 2011.

[44] J. B. Domachowske and H. F. Rosenberg, “Respiratory syncytial virus infection: immune response, immunopathogenesis, and treatment,” *Clinical Microbiology Reviews*, vol. 12, no. 2, pp. 298–309, 1999.
[45] R. Ahmed, L. A. Morrison, and D. M. Knipe, “Persistence of viruses,” in Fields Virology, B. N. Knipe, D. M. Knipe, and P. M. Howley, Eds., pp. 219–249, Lippincott Williams & Wilkins, Philadelphia, Pa, USA, 1996.

[46] N. Sigurs, “Epidemiologic and clinical evidence of a respiratory syncytial virus-reactive airway disease link,” American Journal of Respiratory and Critical Care Medicine, vol. 163, no. 3, pp. 52–56, 2001.

[47] B. NAYLOR, “The shedding of the mucosa of the bronchial tree in asthma,” Thorax, vol. 17, pp. 69–72, 1962.

[48] L. A. Laitinen, M. Heino, and A. Laitinen, “Damage of the airway epithelium and bronchial reactivity in patients with asthma,” American Review of Respiratory Disease, vol. 131, no. 4, pp. 599–606, 1985.

[49] L. Cohen, X. Xueping, J. Tarsi et al., “Epithelial cell proliferation contributes to airway remodeling in severe asthma,” American Journal of Respiratory and Critical Care Medicine, vol. 176, no. 2, pp. 138–145, 2007.

[50] L. Ordoñez, R. Ferrando, D. M. Hyde, H. H. Wong, and J. V. Fahy, “Epithelial desquamation in asthma: artifact or pathology?” American Journal of Respiratory and Critical Care Medicine, vol. 162, no. 6, pp. 3234–3239, 2000.

[51] H. A. Jenkins, C. Cool, S. J. Szefler et al., “Histopathology of severe childhood asthma: a case series,” Chest, vol. 124, no. 1, pp. 32–41, 2003.

[52] C. L. Ordoñez, R. Khassayar, H. H. Wong et al., “Mild and moderate asthma is associated with airway goblet cell hyperplasia and abnormalities in mucin gene expression,” American Journal of Respiratory and Critical Care Medicine, vol. 163, no. 2, pp. 517–523, 2001.

[53] E. Tagaya and J. Tamaoki, “Mechanisms of airway remodeling in asthma,” Allergology International, vol. 56, no. 4, pp. 331–340, 2007.

[54] J. V. Fahy, “Remodeling of the airway epithelium in asthma,” American Journal of Respiratory and Critical Care Medicine, vol. 164, no. 10, pp. S46–51, 2001.

[55] L. Cohn, J. S. Tepper, and K. Bottomly, “Cutting edge: IL-4 independent induction of airway hyperresponsiveness by Th2, but not Th1, cells,” Journal of Immunology, vol. 161, no. 8, pp. 3813–3816, 1998.

[56] D. A. Kuperman, X. Huang, L. L. Koth et al., “Direct effects of interleukin-13 on epithelial cells cause airway hyperreactivity and mucus overproduction in asthma,” Nature Medicine, vol. 8, no. 8, pp. 885–889, 2002.

[57] M. Amishima, M. Munakata, Y. Nasuhara et al., “Expression of epidermal growth factor and epidermal growth factor receptor immunoreactivity in the asthmatic human airway,” American Journal of Respiratory and Critical Care Medicine, vol. 157, no. 6, pp. 1907–1912, 1998.

[58] S. M. Ruddicombe, R. Polosa, A. Richter et al., “Involvement of the epidermal growth factor receptor in epithelial repair in asthma,” FASEB Journal, vol. 14, no. 10, pp. 1362–1374, 2000.

[59] K. Takeyama, J. V. Fahy, and J. A. Nadel, “Relationship of epidermal growth factor receptors to goblet cell production in human bronchi,” American Journal of Respiratory and Critical Care Medicine, vol. 163, no. 2, pp. 511–516, 2001.

[60] P. Demols, J. Simony-Lafontaine, P. Chanez et al., “Cell proliferation in the bronchial mucosa of asthmatics and chronic bronchitics,” American Journal of Respiratory and Critical Care Medicine, vol. 150, no. 1, pp. 214–217, 1994.

[61] H. L. Huber and K. K. Koesler, “The pathology of bronchial asthma,” Archives of Internal Medicine, vol. 30, no. 6, pp. 689–760, 1922.
asthmatic airway inflammation,” *American Journal of Respiratory Cell and Molecular Biology*, vol. 15, no. 3, pp. 404–409, 1996.

[78] L. P. Boulet, M. Belanger, and G. Carrier, “Airway responsiveness and bronchial-wall thickness in asthma with or without fixed airflow obstruction,” *American Journal of Respiratory and Critical Care Medicine*, vol. 152, no. 3, pp. 865–871, 1995.

[79] R. Visse and H. Nagase, “Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry,” *Circulation Research*, vol. 92, no. 8, pp. 827–839, 2003.

[80] A. M. Vignola, L. Riccobono, A. Mirabella et al., “Sputum metalloproteinase-9/tissue inhibitor of metalloproteinase-1 ratio correlates with airflow obstruction in asthma and chronic bronchitis,” *American Journal of Respiratory and Critical Care Medicine*, vol. 158, no. 6, pp. 1945–1950, 1998.

[81] M. Hoshino, Y. Nakamura, J. Sim, J. Shimojo, and S. Isogai, “Increased expression of tissue inhibitor of metalloproteinase-1 and loss of correlation with matrix metalloproteinase-9 by macrophages in asthma,” *Laboratory Investigation*, vol. 79, no. 1, pp. 39–47, 1999.

[82] E. A. Kelly and N. N. Jarjour, “Role of matrix metalloproteinases in asthma,” *Current Opinion in Pulmonary Medicine*, vol. 9, no. 1, pp. 28–33, 2003.

[83] M. Hyytiäinen, C. Penttinen, and J. Keski-Oja, “Latent TGF-β binding proteins: extracellular matrix association and roles in TGF-β activation,” *Critical Reviews in Clinical Laboratory Sciences*, vol. 41, no. 3, pp. 233–264, 2004.

[84] M. A. Swartz, D. J. Tschumperlin, R. D. Kamm, and J. M. Drazen, “Mechanical stress is communicated between different cell types to elicit matrix remodeling,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 98, no. 11, pp. 6180–6185, 2001.

[85] A. T. Hastie, W. K. Kraft, K. B. Nyce et al., “Asthmatic epithelial cell proliferation and stimulation of collagen production: human asthmatic epithelial cells stimulate collagen type III production by human lung myofibroblasts after segmental allergen challenge,” *American Journal of Respiratory and Critical Care Medicine*, vol. 165, no. 2, pp. 266–272, 2002.

[86] P. E. Redington, J. Madden, A. J. Frew et al., “Transforming growth factor-β1 in asthma: measurement in bronchoalveolar lavage fluid,” *American Journal of Respiratory and Critical Care Medicine*, vol. 156, no. 2, pp. 642–647, 1997.

[87] S. Beqaj, S. Jakkaraju, R. R. Mattingly, D. Pan, and L. Schuger, “High RhoA activity maintains the undifferentiated mesenchymal cell phenotype, whereas RhoA down-regulation by laminin-2 induces smooth muscle myogenesis,” *Journal of Cell Biology*, vol. 156, no. 5, pp. 893–903, 2002.

[88] S. J. Hirst, J. G. Martin, J. V. Bonacci et al., “Proliferative aspects of airway smooth muscle,” *Journal of Allergy and Clinical Immunology*, vol. 114, no. 2, pp. S2–S17, 2004.

[89] M. Schmidt, G. Sun, M. A. Stacey, L. Mori, and S. Mattoli, “Identification of circulating fibrocytes as precursors of bronchial myofibroblasts in asthma,” *Journal of Immunology*, vol. 171, no. 1, pp. 380–389, 2003.

[90] C. Bergeron, W. Al-Ramli, and Q. Hamid, “Remodeling in asthma,” *Proceedings of the American Thoracic Society*, vol. 6, no. 3, pp. 301–305, 2009.

[91] S. Hossain, “Quantitative measurement of bronchial muscle in men with asthma,” *American Review of Respiratory Disease*, vol. 107, no. 1, pp. 99–109, 1973.

[92] A. M. Freyer, S. R. Johnson, and I. P. Hall, “Effects of growth factors and extracellular matrix on survival of human airway smooth muscle cells,” *American Journal of Respiratory and Critical Care Medicine*, vol. 25, no. 5, pp. 569–576, 2001.

[93] P. H. Howarth, A. J. Knox, Y. Amrani, O. Tliba, R. A. Panettieri, and M. Johnson, “Synthetic responses in airway smooth muscle,” *Journal of Allergy and Clinical Immunology*, vol. 114, no. 2, supplement 1, pp. S32–S50, 2004.

[94] K. Page, J. Li, Y. Wang, S. Kartha, R. G. Pestell, and M. B. Hershenson, “Regulation of cyclin D(1) expression and DNA synthesis by phosphatidylinositol 3-kinase in airway smooth muscle cells,” *American Journal of Respiratory and Critical Care Medicine*, vol. 23, no. 4, pp. 436–443, 2000.

[95] M. J. Orsini, V. P. Krymskaya, A. J. Essterhas, J. L. Benovic, R. A. Panettieri, and R. B. Penn, “MAPK superfamily activation in human airway smooth muscle: mitogenesis requires prolonged p42/p44 activation,” *American Journal of Physiology*, vol. 277, no. 3, pp. L147–L1488, 1999.

[96] J. M. Madison, “Migration of airway smooth muscle cells,” *American Journal of Respiratory Cell and Molecular Biology*, vol. 29, no. 1, pp. 8–11, 2003.

[97] M. Hoshino, M. Takahashi, and N. Aoike, “Expression of vascular endothelial growth factor, basic fibroblast growth factor, and angiogenin immunoreactivity in asthmatic airways and its relationship to angiogenesis,” *Journal of Allergy and Clinical Immunology*, vol. 107, no. 2, pp. 295–301, 2001.

[98] A. M. Vignola, L. Riccobono, A. Mirabella et al., “Increased expression of tissue inhibitor of metalloproteinase-1 and loss of correlation with matrix metalloproteinase-9 by macrophages in asthma,” Laboratory Investigation, vol. 79, no. 1, pp. 39–47, 1999.

[99] G. A. Kelly and N. N. Jarjour, “Role of matrix metalloproteinases in asthma,” *Current Opinion in Pulmonary Medicine*, vol. 9, no. 1, pp. 28–33, 2003.

[100] P. E. Redington, J. Madden, A. J. Frew et al., “Transforming growth factor-β1 in asthma: measurement in bronchoalveolar lavage fluid,” *American Journal of Respiratory and Critical Care Medicine*, vol. 156, no. 2, pp. 642–647, 1997.

[101] S. Beqaj, S. Jakkaraju, R. R. Mattingly, D. Pan, and L. Schuger, “High RhoA activity maintains the undifferentiated mesenchymal cell phenotype, whereas RhoA down-regulation by laminin-2 induces smooth muscle myogenesis,” *Journal of Cell Biology*, vol. 156, no. 5, pp. 893–903, 2002.

[102] S. J. Hirst, J. G. Martin, J. V. Bonacci et al., “Proliferative aspects of airway smooth muscle,” *Journal of Allergy and Clinical Immunology*, vol. 114, no. 2, pp. S2–S17, 2004.

[103] M. Schmidt, G. Sun, M. A. Stacey, L. Mori, and S. Mattoli, “Identification of circulating fibrocytes as precursors of bronchial myofibroblasts in asthma,” *Journal of Immunology*, vol. 171, no. 1, pp. 380–389, 2003.

[104] C. Bergeron, W. Al-Ramli, and Q. Hamid, “Remodeling in asthma,” *Proceedings of the American Thoracic Society*, vol. 6, no. 3, pp. 301–305, 2009.
[108] Yong Chul Lee and Hern Ku Lee, “Vascular endothelial growth factor in patients with acute asthma,” *Journal of Allergy and Clinical Immunology*, vol. 107, no. 6, p. 1106, 2001.

[109] T. R. Bai and D. A. Knight, “Structural changes in the airways in asthma: observations and consequences,” *Clinical Science*, vol. 108, no. 6, pp. 463–477, 2005.

[110] S. Siddiqui and J. G. Martin, “Structural aspects of airway remodeling in asthma,” *Current Allergy and Asthma Reports*, vol. 8, no. 6, pp. 540–547, 2008.

[111] R. K. Lambert, B. R. Wiggs, K. Kuwano, J. C. Hogg, and P. D. Pare, “Functional significance of increased airway smooth muscle in asthma and COPD,” *Journal of Applied Physiology*, vol. 74, no. 6, pp. 2771–2781, 1993.

[112] M. Yanai, K. Sekizawa, T. Ohrui, H. Sasaki, and T. Takishima, “Site of airway obstruction in pulmonary disease: direct measurement of intrabronchial pressure,” *Journal of Applied Physiology*, vol. 72, no. 3, pp. 1016–1023, 1992.

[113] E. M. Wagner, E. R. Bleeker, S. Perfutt, and M. C. Liu, “Direct assessment of small airways reactivity in human subjects,” *American Journal of Respiratory and Critical Care Medicine*, vol. 157, no. 2, pp. 447–452, 1998.

[114] D. A. Kaminsky, S. E. Wenzel, C. Carcano, D. Gurka, D. Feldsien, and C. G. Irvin, “Hyperpnea-induced changes in parenchymal lung mechanics in normal subjects and in asthmatics,” *American Journal of Respiratory and Critical Care Medicine*, vol. 155, no. 4, pp. 1260–1266, 1997.

[115] T. Winkler and J. G. Venegas, “Complex airway behavior and paradoxical responses to bronchoprovocation,” *Journal of Applied Physiology*, vol. 103, no. 2, pp. 655–663, 2007.

[116] K. R. Lutchen and H. Gillis, “Relationship between heterogeneous changes in airway morphometry and lung resistance and elastance,” *Journal of Applied Physiology*, vol. 83, no. 4, pp. 1192–1201, 1997.

[117] R. H. Brown, C. J. Herold, C. A. Hirshman, E. A. Zerhouni, and W. Mitzner, “Individual airway constrictor response heterogeneity to histamine assessed by high-resolution computed tomography,” *Journal of Applied Physiology*, vol. 74, no. 6, pp. 2615–2620, 1993.

[118] R. H. Brown and W. Mitzner, “The myth of maximal airway responsiveness in vivo,” *Journal of Applied Physiology*, vol. 85, no. 6, pp. 2012–2017, 1998.

[119] R. H. Brown, P. Croiselle, B. Mudge, F. B. Diemer, S. Perfutt, and A. Togias, “Airway narrowing in healthy humans inhaling methacholine without deep inspirations demonstrated by HRCT,” *American Journal of Respiratory and Critical Care Medicine*, vol. 161, no. 4, pp. 1256–1263, 2000.

[120] H. L. Gillis and K. R. Lutchen, “Airway remodeling in asthma amplifies heterogeneities in smooth muscle shortening causing hyperresponsiveness,” *Journal of Applied Physiology*, vol. 86, no. 6, pp. 2001–2012, 1999.

[121] K. R. Lutchen, A. Jensen, H. Atileh et al., “Airway constriction pattern is a central component of asthma severity: the role of deep inspirations,” *American Journal of Respiratory and Critical Care Medicine*, vol. 164, no. 2, pp. 207–215, 2001.

[122] J. G. Martin, A. Duguet, and D. H. Eidelman, “The contribution of airway smooth muscle to airway narrowing and airway hyperresponsiveness in disease,” *European Respiratory Journal*, vol. 16, no. 2, pp. 349–354, 2000.

[123] T. Björck, L. E. Gustafsson, and S. E. Dahlen, “Isolated bronchi from asthmatics are hyperresponsive to adenosine, which apparently acts indirectly by liberation of leukotrienes and histamine,” *American Review of Respiratory Disease*, vol. 145, no. 5, pp. 1087–1091, 1992.

[124] R. W. Mitchell, E. Ruhlmann, H. Magnusson, A. R. Leff, and K. F. Rabe, “Passive sensitization of human bronchi augments smooth muscle shortening velocity and capacity,” *American Journal of Physiology*, vol. 267, no. 2, pp. L218–L222, 1994.

[125] T. R. Bai, “Abnormalities in airway smooth muscle in fatal asthma: a comparison between trachea and bronchus,” *American Review of Respiratory Disease*, vol. 143, no. 2, pp. 441–443, 1991.

[126] S. D. Whicker, C. L. Armour, and J. L. Black, “Responsiveness of bronchial smooth muscle from asthmatic patients to relaxant and contractile agonists,” *Pulmonary Pharmacology*, vol. 1, no. 1, pp. 25–31, 1988.

[127] N. C. Thomson, “In vivo versus in vitro human airway responsiveness to different pharmacologic stimuli,” *American Review of Respiratory Disease*, vol. 136, no. 4, pp. 558–562, 1987.

[128] R. Léguellette and A. M. Lauzon, “Molecular mechanics of smooth muscle contractile proteins in airway hyperresponsiveness and asthma,” *Proceedings of the American Thoracic Society*, vol. 5, no. 1, pp. 40–46, 2008.

[129] R. Léguellette, M. Laviolette, C. Bergeron et al., “Myosin, transgelin, and myosin light chain kinase expression and function in asthma,” *American Journal of Respiratory and Critical Care Medicine*, vol. 179, no. 3, pp. 194–204, 2009.

[130] X. Ma, Z. Cheng, H. Kong et al., “Changes in biophysical and biochemical properties of single bronchial smooth muscle cells from asthmatic subjects,” *American Journal of Physiology - Lung Cellular and Molecular Physiology*, vol. 283, no. 6, pp. L1181–L1189, 2002.

[131] A. Duguet, K. Biyah, E. Minshall et al., “Bronchial responsiveness among inbred mouse strains: role of airway smooth-muscle shortening velocity,” *American Journal of Respiratory and Critical Care Medicine*, vol. 161, no. 3, pp. 839–848, 2000.

[132] J. W. Wilson, X. Li, and M. C. F. Pain, “The lack of distensibility of asthmatic airways,” *American Review of Respiratory Disease*, vol. 148, no. 3, pp. 806–809, 1993.

[133] H. J. L. Brackel, O. F. Pedersen, P. G. H. Mulder, S. E. Overbeek, K. F. Kerrebijn, and J. M. Bogaard, “Central airways behave more stiffly during forced expiration in patients with asthma,” *American Journal of Respiratory and Critical Care Medicine*, vol. 162, no. 3, pp. 896–904, 2000.

[134] C. Ward, D. P. Johns, R. Bish et al., “Reduced airway distensibility, fixed airflow limitation, and airway wall remodeling in asthma,” *American Journal of Respiratory and Critical Care Medicine*, vol. 164, no. 9, pp. 1718–1721, 2001.

[135] S. Pitchford and C. Page, “Extracellular matrix composition influences the resistance of airway remodelling events towards glucocorticoid treatment,” *British Journal of Pharmacology*, vol. 138, no. 7, pp. 1181–1182, 2003.

[136] J. J. Fredberg, D. Inouye, B. Miller et al., “Airway smooth muscle, tidal stretches, and dynamically determined contractile states,” *American Journal of Respiratory and Critical Care Medicine*, vol. 156, no. 6, pp. 1752–1759, 1997.

[137] S. J. Gunst and J. Q. Stropp, “Pressure-volume and lengthstress relationships in canine bronchi in vitro,” *Journal of Applied Physiology*, vol. 64, no. 6, pp. 2522–2531, 1988.

[138] T. R. Bai, J. H. T. Bates, V. Brusasco et al., “On the terminology for describing the length-force relationship and its changes in airway smooth muscle,” *Journal of Applied Physiology*, vol. 97, no. 6, pp. 2029–2034, 2004.

[139] B. E. McParland, P. T. Macklem, and P. D. Paré, “Airway wall remodeling: friend or foe?” *Journal of Applied Physiology*, vol. 95, no. 1, pp. 426–434, 2003.
[140] A. Fust and N. L. Stephens, “Mechanical plasticity and contractile properties of airway smooth muscle,” *Canadian Journal of Physiology and Pharmacology*, vol. 83, no. 10, pp. 865–868, 2005.

[141] T. R. Bai, J. Cooper, T. Koelmeyer, P. D. Pare, and T. D. Weir, “The effect of age and duration of disease on airway structure in fatal asthma,” *American Journal of Respiratory and Critical Care Medicine*, vol. 162, no. 2, pp. 663–669, 2000.

[142] N. J. Vanacker, E. Palms, J. C. Kips, and R. A. Pauwels, “Fluticasone inhibits but does not reverse allergen-induced structural airway changes,” *American Journal of Respiratory and Critical Care Medicine*, vol. 163, no. 3, pp. 674–679, 2001.

[143] S. T. Holgate, “Novel targets of therapy in asthma,” *Current Opinion in Pulmonary Medicine*, vol. 15, no. 1, pp. 63–71, 2009.

[144] C. Ward, M. Pais, R. Bish et al., “Airway inflammation, basement membrane thickening and bronchial hyperresponsiveness in asthma,” *Thorax*, vol. 57, no. 4, pp. 309–316, 2002.

[145] L. P. Boulet, H. Turcotte, M. Laviolette et al., “Airway hyperresponsiveness, inflammation, and subepithelial collagen deposition in recently diagnosed versus long-standing mild asthma: influence of inhaled corticosteroids,” *American Journal of Respiratory and Critical Care Medicine*, vol. 162, no. 4, pp. 1308–1313, 2000.

[146] J. Tonascia, N. F. Adkinson, B. Bender et al., “Long-term effects of budesonide or nedocromil in children with asthma,” *New England Journal of Medicine*, vol. 343, no. 15, pp. 1054–1063, 2000.

[147] H. H. Shen, S. I. Ochkur, M. P. McGarry et al., “A causative relationship exists between eosinophils and the development of allergic pulmonary pathologies in the mouse,” *Journal of Immunology*, vol. 170, no. 6, pp. 3296–3305, 2003.

[148] C. Büttner, A. Lun, T. Splettstoesser, G. Kunkel, and H. Renz, “Monoclonal anti-interleukin-5 treatment suppresses eosinophil but not T-cell functions,” *European Respiratory Journal*, vol. 21, no. 5, pp. 799–803, 2003.

[149] P. T. F. Flood-Page, A. N. Menzies-Gow, A. B. Kay, and D. S. Robinson, “Eosinophil’s role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway,” *American Journal of Respiratory and Critical Care Medicine*, vol. 167, no. 2, pp. 199–204, 2003.

[150] J. C. Kips, B. J. O’Connor, S. J. Langley et al., “Effect of SCH55700, a humanized anti-human interleukin-5 antibody, in severe persistent asthma: a pilot study,” *American Journal of Respiratory and Critical Care Medicine*, vol. 167, no. 12, pp. 1655–1659, 2003.

[151] M. J. Leckie, A. Ten Brinke, J. Khan et al., “Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response,” *Lancet*, vol. 356, pp. 2144–2148, 2000.

[152] P. Haldar, C. E. Brightling, B. Hargadon et al., “Mepolizumab and exacerbations of refractory eosinophilic asthma,” *New England Journal of Medicine*, vol. 360, no. 10, pp. 973–984, 2009.

[153] P. Nair, M. M. M. Pizzichini, M. Kjarsgaard et al., “Mepolizumab for prednisone-dependent asthma with sputum eosinophilia,” *New England Journal of Medicine*, vol. 360, no. 10, pp. 985–993, 2009.

[154] J. G. Ayres, B. Higgins, E. R. Chilver, G. Ayre, M. Blogg, and H. Fox, “Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma,” *Allergy*, vol. 59, no. 7, pp. 701–708, 2004.

[155] S. T. Holgate, A. G. Chuchalin, J. Hébert et al., “Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma,” *Clinical and Experimental Allergy*, vol. 34, no. 4, pp. 632–638, 2004.

[156] R. Buhl, G. Hanf, M. Solér et al., “The anti-IgE antibody omalizumab improves asthma-related quality of life in patients with allergic asthma,” *European Respiratory Journal*, vol. 20, no. 5, pp. 1088–1094, 2002.

[157] R. Buhl, M. Solér, J. Matz et al., “Omalizumab provides long-term control in patients with moderate-to-severe allergic asthma,” *European Respiratory Journal*, vol. 20, no. 1, pp. 73–78, 2002.

[158] W. Busse, J. Corren, B. Q. Lanier et al., “Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma,” *Journal of Allergy and Clinical Immunology*, vol. 108, no. 2, pp. 184–190, 2001.

[159] M. Humbert, R. Beasley, J. Ayres et al., “Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE,” *Allergy*, vol. 60, no. 3, pp. 309–316, 2005.

[160] M. Diane Lougheed, C. Lemière, S. D. Dell et al., “Canadian thoracic society asthma management continuum—2010 consensus summary for children six years of age and over, and adults,” *Canadian Respiratory Journal*, vol. 17, no. 1, pp. 15–24, 2010.

[161] P. P. Belliveau, “Omalizumab: a monoclonal anti-IgE antibody,” *MedGenMed Medscape General Medicine*, vol. 7, no. 1, p. 27, 2005.

[162] R. Djukanović, S. J. Wilson, M. Kraft et al., “Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma,” *American Journal of Respiratory and Critical Care Medicine*, vol. 170, no. 6, pp. 583–893, 2004.

[163] J. D. Miller, G. Cox, L. Vincic, C. M. Lombard, B. E. Loomas, and C. J. Danek, “A prospective feasibility study of bronchial thermoplasty in the human airway,” *Chest*, vol. 127, no. 6, pp. 1999–2006, 2005.

[164] M. Castro, A. S. Rubin, M. Laviolette et al., “Effectiveness and safety of bronchial thermoplasty in the treatment of severe asthma: a multicenter, randomized, double-blind, sham-controlled clinical trial,” *American Journal of Respiratory and Critical Care Medicine*, vol. 181, no. 2, pp. 116–124, 2010.

[165] G. Cox, N. C. Thomson, A. S. Rubin et al., “Asthma control during the year after bronchial thermoplasty,” *New England Journal of Medicine*, vol. 356, no. 13, pp. 1327–1337, 2007.

[166] N. C. Thomson, A. S. Rubin, R. M. Niven et al., “Long-term (5 year) safety of bronchial thermoplasty: asthma Intervention Research (AIR) trial,” *BMC Pulmonary Medicine*, vol. 11, no. 1, p. 8, 2011.

[167] G. Cox et al., “Long-term safety of bronchial thermoplasty (BT): 3 year data from multiple studies,” *American Journal of Respiratory and Critical Care Medicine*, vol. 179, p. A2780, 2009.